[{"address1": "25 North 38th Street", "address2": "11th Floor", "city": "Philadelphia", "state": "PA", "zip": "19104", "country": "United States", "phone": "267 817 5790", "website": "https://www.centurytx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.", "fullTimeEmployees": 140, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brent  Pfeiffenberger M.B.A., Pharm.D.", "age": 46, "title": "President, CEO & Chairman", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 1708667, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gregory  Russotti Ph.D.", "age": 57, "title": "Chief Technology & Manufacturing Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 812631, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas  Carr CPA", "title": "Senior VP of Finance & Operations, Principal Financial Officer and Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chad A. Cowan Ph.D.", "age": 52, "title": "Chief Scientific Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Megan  Bilson", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Michael  Naso Ph.D.", "title": "Senior VP of Cell Engineering", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elizabeth  Devlin", "title": "VP & Head of Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.31, "open": 2.33, "dayLow": 2.08, "dayHigh": 2.58, "regularMarketPreviousClose": 2.31, "regularMarketOpen": 2.33, "regularMarketDayLow": 2.08, "regularMarketDayHigh": 2.58, "payoutRatio": 0.0, "beta": 1.725, "forwardPE": -2.4948454, "volume": 2210889, "regularMarketVolume": 2210889, "averageVolume": 1867436, "averageVolume10days": 3927400, "averageDailyVolume10Day": 3927400, "bid": 2.37, "ask": 2.46, "bidSize": 3, "askSize": 3, "marketCap": 211520864, "fiftyTwoWeekLow": 0.342, "fiftyTwoWeekHigh": 2.58, "allTimeHigh": 32.899, "allTimeLow": 0.342, "priceToSalesTrailing12Months": 1.8663002, "fiftyDayAverage": 0.96178, "twoHundredDayAverage": 0.649165, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 123491160, "profitMargins": -0.23366, "floatShares": 20250880, "sharesOutstanding": 87405311, "sharesShort": 325386, "sharesShortPriorMonth": 608275, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.0037, "heldPercentInsiders": 0.25474, "heldPercentInstitutions": 1.14624, "shortRatio": 0.23, "shortPercentOfFloat": 0.0053, "impliedSharesOutstanding": 87405311, "bookValue": 2.038, "priceToBook": 1.1874386, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -26482000, "trailingEps": -0.32, "forwardEps": -0.97, "enterpriseToRevenue": 1.09, "enterpriseToEbitda": -12.597, "52WeekChange": 1.6400001, "SandP52WeekChange": 0.14987159, "quoteType": "EQUITY", "currentPrice": 2.42, "targetHighPrice": 6.0, "targetLowPrice": 2.0, "targetMeanPrice": 3.5, "targetMedianPrice": 3.0, "recommendationMean": 1.75, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 132749000, "totalCashPerShare": 1.52, "ebitda": -9803000, "totalDebt": 44957000, "quickRatio": 6.049, "currentRatio": 6.252, "totalRevenue": 113337000, "debtToEquity": 25.493, "revenuePerShare": 1.317, "returnOnAssets": -0.044749998, "returnOnEquity": -0.14236, "grossProfits": 7990000, "freeCashflow": 10888000, "operatingCashflow": -112022000, "grossMargins": 0.0705, "ebitdaMargins": -0.086490005, "operatingMargins": -0.20004, "financialCurrency": "USD", "symbol": "IPSC", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "esgPopulated": false, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1769216371, "regularMarketTime": 1769202002, "exchange": "NCM", "messageBoardId": "finmb_626518430", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1624023000000, "postMarketChangePercent": -0.41322273, "postMarketPrice": 2.41, "postMarketChange": -0.00999999, "regularMarketChange": 0.11, "regularMarketDayRange": "2.08 - 2.58", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1867436, "fiftyTwoWeekLowChange": 2.078, "fiftyTwoWeekLowChangePercent": 6.0760236, "fiftyTwoWeekRange": "0.342 - 2.58", "fiftyTwoWeekHighChange": -0.15999985, "fiftyTwoWeekHighChangePercent": -0.062015448, "fiftyTwoWeekChangePercent": 164.00002, "earningsTimestamp": 1763040600, "earningsTimestampStart": 1763040600, "earningsTimestampEnd": 1763040600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.32, "epsForward": -0.97, "epsCurrentYear": -0.13, "priceEpsCurrentYear": -18.615385, "fiftyDayAverageChange": 1.45822, "fiftyDayAverageChangePercent": 1.5161679, "twoHundredDayAverageChange": 1.7708352, "twoHundredDayAverageChangePercent": 2.7278662, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "longName": "Century Therapeutics, Inc.", "shortName": "Century Therapeutics, Inc.", "regularMarketChangePercent": 4.76191, "regularMarketPrice": 2.42, "ipoExpectedDate": "2021-06-18", "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "displayName": "Century Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-24"}]